Percorrendo por Autor André Poisl Fay

Ir para: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ou digite as primeiras letras:  
Mostrando regs. 1 a 15 de 15
Data de publicaçãoTítuloAutor(es)
2018Análise da expressão imuno-histoquímica do fator tecidual no carcinoma gástrico: correlações com prognóstico e sobrevida.TONETO, MARCELO GARCIA; DEPAULA, PEDRO LUCAS; DEBON, LETÍCIA, et al
2015Cost of preventing an event (COPE) of enzalutamide versus abiraterone plus prednisone in men with metastatic castration-resistant prostate cancer under the Brazilian private health care system perspectiveStephen Doral Stefani; Vanessa Teich; André Poisl Fay, et al
2017Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trialsMOREIRA, RAPHAEL B.; Marcio Debiasi; FRANCINI, EDOARDO, et al
2015HER2 as a target in invasive urothelial carcinomaBELLMUNT, JOAQUIM; WERNER, LILLIAN; BAMIAS, ARISTOTLE, et al
2018Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials DatabaseAndré Poisl Fay; MCKAY, RANA R.; LIN, XUN, et al
2018Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinomaLana Hamieh; CHOUEIRI, T. K.; B ogorek, et al
2016Número necessário a tratar (NNT) e custo por evento evitado (COPE) de enzalutamida e acetato de abiraterona para o tratamento de câncer de próstata resistente à castração que falharam a terapia de privação de androgênioSTEFANI, STEPHEN; SASSE, ANDRÉ; André Poisl Fay, et al
2016Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell CarcinomaDE VELASCO, GUILLERMO; GRAY, KATHRYN P.; HAMIEH, LANA, et al
2015Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studyAndré Poisl Fay; SIGNORETTI, SABINA; CALLEA, MARCELLA, et al
2016Quality of life of cancer patients on the wave of immunotherapyRAMOS, FERNANDA B. PRUSKI; André Poisl Fay
2017Second-Line Treatment of Metastatic Renal Cell Carcinoma: Systematic Review and Network Meta-AnalysisCAUDURO, C. G. S.; Pablo M Barrios; Pedro Crivelaro, et al
2015Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial TumorsBELLMUNT, JOAQUIM; WERNER, LILLIAN; LEOW, JEFFREY J., et al
2018The Clinical Activity of PD-1/PD-L1 inhibitors in Metastatic Non-Clear Cell Renal Cell CarcinomaMCKAY, RANA R.; BOSSÉ, DOMINICK; XIE, WANLING, et al
2017The impact of bone metastasis location in the clinical outcome of patients with metastatic renal cell carcinoma (mRCC): an analysis from the Latin American Renal Cancer Group (LARCG)CLAVIJO, DIEGO ABREU; André Poisl Fay; GROUP LARCG
2016The Management of Immune-related Adverse Events Associated with Immune Checkpoint BlockadeAndré Poisl Fay; Raphael Brandao Moreira; Paulo R. S.Nunes Filho, et al